|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from...
The most recent short interest data was recently released by the NASDAQ for the 09/15/2014 settlement date, and ARIAD Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 10.65 "days to cover" versus the median component at 6.91.
Activist investor Alex Denner is gaining an ally on Ariad's Board.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Cramer likes Araid Pharmaceuticals and Occidental Petroleum and is sticking with his Taser recommendation.
Cramer wants Apple, Microsoft and Dow Chemical on his team.
In trading on Tuesday, shares of ARIAD Pharmaceuticals, Inc. crossed above their 200 day moving average of $6.49, changing hands as high as $6.65 per share.
Ariad Pharmaceuticals (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune (ITMN) has led the biotech sector higher.
Insiders at these companies have been scooping up shares of their own stock lately.
Ariad Pharmaceuticals (ARIA) shares are down after the company reported second quarter earnings and revenue that failed to meet analysts expectations.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig ® (ponatinib).
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights...
These under-$10 biotech stocks are within range of triggering breakout trades.
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate
Here's how to trade some of the most active stocks on the market today.
The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens.
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited...
The most recent short interest data has been released by the NASDAQ for the 06/30/2014 settlement date, which shows a 6,622,315 share increase in total short interest for ARIAD Pharmaceuticals, Inc. , to 48,055,172, an increase of 15.98% since 06/13/2014.
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
By Alex Gavrish, Etalon Investment Research; author of "Wall Street Back To Basics" The main beneficiary of a recent acquisition of Idenix Pharmaceuticals Inc (NASDAQ:IDIX) by Merck & Co., I...
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the recent appointments of three executives with extensive pharmaceutical industry experience in the areas of global quality, medical affairs, and drug ...
UBS decreased its price target on Ariad Pharmaceuticals (ARIA) to $7 and set a "neutral" rating. The firm noted limited near-term drivers of upside risk.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of $200 million aggregate principal amount of its 3.
Ariad Pharmaceuticals (ARIA) fell in after-hours trading Wednesday after the oncology company announced a proposed $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the “Notes”)...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.